Skip to main content

Medtronic Value Stock - Dividend - Research Selection

Medtronic

ISIN: IE00BTN1Y115 , WKN: A14M2J

Market price date:
Market price:  


Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Ratios
Key figures
Cash flow
P/C
 
P/FC
Balance sheet
ROI
ROE
Income statement
P/E
Div. Yield %
P/B
P/S


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



Description Data
Symbol
Market Capitalization USD
Country
Indices
Sectors
Raw Data Source
Stock Split
Internet


Description of the company

Medtronic plc manufactures and sells device-based medical therapies to hospitals, physicians, clinicians, and patients worldwide. The company\'s Cardiac and Vascular Group segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; diagnostics and monitoring devices; mechanical circulatory support, TYRX, and AF products; and remote monitoring and patient-centered software. It also provides transcatheter heart valves, percutaneous coronary intervention stents, surgical valve replacement and repair products, endovascular stent grafts, peripheral vascular products, and products to treat superficial and deep venous diseases. Its Minimally Invasive Therapies Group segment offers surgical care, wound closure, electrosurgical, hernia mechanical device, mesh implant, ablation, interventional lung, ventilator, capnography, airway, sensor, monitor, compression, dialysis, enteral feeding, wound care, and medical surgical products; stapling, vessel sealing, fixation, and hardware instruments; and gastrointestinal, temperature management, inhalation therapy, and renal care solutions.

 

The company\'s Restorative Therapies Group segment offers products for spine, bone graft substitutes, biologic products, trauma, implantable neurostimulation therapies, and drug delivery systems for the treatment of chronic pain, movement disorders, obsessive-compulsive disorder, overactive bladder, urinary retention, fecal incontinence, and gastroparesis, as well as products to treat conditions of the ear, nose, and throat; and systems that incorporate energy surgical instruments. It also provides image-guided surgery and intra-operative imaging systems; and therapies for vasculature in and around the brain. The company\'s Diabetes Group segment offers insulin pumps and consumables, continuous glucose monitoring systems, and Web-based therapy management software.

 

The company was founded in 1949 and is headquartered in Dublin, Ireland.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov,


NEWS


Watch 5 AI-Powered Medical Stocks for a Strong Portfolio in 2026

2026-01-05
LLY, MDT, ISRG, REGN and JNJ are five defensive medical stocks using AI to drive growth, diagnostics and innovation into 2026.

Nia Therapeutics Publishes Peer-Reviewed Validation of a 60-Channel Brain Implant for Closed-Loop Neurostimulation

2026-01-04
ALLSTON, Mass., January 04, 2026--Nia Therapeutics announced publication in Brain Stimulation of the first in vivo validation of its Smart Neurostimulation System (SNS), a wireless, implantable brain-computer interface designed for closed-loop treatment of memory disorders.

Coloplast - Premium Valuation And Pedestrian Results Have Been A Bad Mix

2026-01-02
Coloplast (CLPBY) struggles with misses, CEO search and execution risks, but U.S./EM growth offers upside.

2 Top Dividend Stocks to Buy for 2026

2026-01-02
Both can be great portfolio anchors.

CEO shake-ups in 2026: Why Berkshire isn't the one to watch

2025-12-31
From pay packages to succession, investors have been keeping a close eye on CEOs in 2025. Harvard University executive education fellow and former Medtronic (MDT) CEO Bill George joins Market Domination to discuss the CEOs he's watching in 2026. To watch more expert insights and analysis on the latest market action, check out more Market Domination.

How Is Boston Scientific's Cardiovascular Growth Path Shaping Up?

2025-12-31
BSX's $50B cardiovascular business aims to outpace market growth across EP, WATCHMAN, ICTx and more.

Best Dividend Aristocrats For January 2026

2025-12-31

Bearish Options Activity Emerges on Medtronic plc (MDT) Despite Long-Term Growth Outlook

2025-12-30
We recently compiled a list of the 7 Most Promising Robotics Stocks According to Wall Street Analysts. Medtronic plc stands fifth among the most promising stocks. TheFly reported on December 18 that Truist Securities maintained its Hold recommendation on MDT but lowered its price objective to $107.00 from $110.00. This revision followed an update to […]

Got $500? 3 Dividend-Paying Healthcare Stocks to Buy and Hold Forever

2025-12-30
Investors seeking reliable dividends will find that this trio of healthcare stocks offers an exciting combination of safety, growth, and income.

The Edwards Lifesciences Dilemma Persists: Strong Growth Potential, High Price

2025-12-29
Edwards Lifesciences stock is supported by its growth outlook and the impact of clinical advances. See why investors should await better entry points.